Micell's Optimism In MiStent Biosorbable Polymer Stent Grows With Retrospective Study
Executive Summary
A retrospective propensity-matched comparison of Micell’s MiStent sirolimus-eluting absorbable polymer coronary stent system to Abbott’s popular Xience V everolimus-eluting stent suggests that MiStent has a good chance of outperforming Xience in the DESSOLVE III randomized trial.
You may also be interested in...
EuroPCR 2017: TAVR Continues To Beat Surgery; Bioabsorbable Stents Not Going Away
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.
SafetyCall On What Cosmetics Companies Need In Their AE Reporting Systems
Companies preparing for adverse event reporting and recordkeeping deadlines on 29 December under new cosmetics regulations should ensure they have systems in place for netting complaints across media, triaging reports, and making speedy weight-of-evidence determinations, said SafetyCall International’s Rick Kingston at IBA’s recent FDA regulatory workshop.
Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.